deltatrials
Suspended PHASE1 INTERVENTIONAL 1-arm NCT01841463

Study of an Oral Cdk Inhibitor Administered With an Oral BRAF Inhibitor in Patients With Advanced or Inoperable Malignant Melanoma With BRAF Mutation

An Open Label, Multicenter, Phase I Extension Study of an Oral Cdk Inhibitor P1446A-05 Administered With an Oral BRAF Inhibitor Vemurafenib (Zelboraf®) in Patients With Advanced or Inoperable Malignant Melanoma With BRAF Mutation

Sponsor: Melanoma Research Foundation Breakthrough Consortium

Conditions Advanced or Inoperable Malignant Melanoma With BRAF Mutation
Interventions P1446A-05 Vemurafenib (Zelboraf®)
Updated 7 times since 2017 Last updated: Sep 3, 2014 Started: Aug 31, 2013 Primary completion: Mar 31, 2015 Completion: Mar 31, 2016
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Suspended

Sponsor decision not related to patient safety

This PHASE1 trial investigates Advanced or Inoperable Malignant Melanoma With BRAF Mutation and is currently suspended. Melanoma Research Foundation Breakthrough Consortium leads this study, which shows 7 recorded versions since 2013 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotSuspended~Feb 2017 – ~Jun 2018 · 16 months · monthly snapshotSuspended~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotSuspended~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotSuspended~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotSuspended~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotSuspended~Sep 2025 – present · 12 months · monthly snapshotSuspended

Change History

7 versions recorded

  1. Sep 2025 — Present [monthly]

    Suspended PHASE1

  2. Sep 2024 — Sep 2025 [monthly]

    Suspended PHASE1

  3. Jul 2024 — Sep 2024 [monthly]

    Suspended PHASE1

  4. Jan 2021 — Jul 2024 [monthly]

    Suspended PHASE1

  5. Jun 2018 — Jan 2021 [monthly]

    Suspended PHASE1

▶ Show 2 earlier versions

  1. Feb 2017 — Jun 2018 [monthly]

    Suspended PHASE1

  2. Jan 2017 — Feb 2017 [monthly]

    Suspended PHASE1

    First recorded

Aug 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Melanoma Research Foundation Breakthrough Consortium
  • Piramal Enterprises Limited
Data source: Piramal Enterprises Limited

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations